NASDAQ:ATRA - Atara Biotherapeutics Stock Price, Price Target & More

Get Started

$51.05 +1.35 (+2.72 %)

(As of 05/25/2018 07:21 AM ET)

Previous Close$49.70

Today's Range$49.45 - $51.35

52-Week Range$11.80 - $54.45

Volume317,050 shs

Average Volume581,629 shs

Market Capitalization$2.18 billion

P/E Ratio-12.76

Dividend YieldN/A

Beta2.55

About Atara Biotherapeutics (NASDAQ:ATRA)

Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. The company is developing tabelecleucel, an advanced T-cell immunotherapy that is Phase III clinical trials for the treatment of rituximab-refractory epstein-barr virus (EBV) associated post-transplant lymphoproliferative disorder, as well as other EBV associated hematologic and solid tumors, including nasopharyngeal carcinoma. It is also developing ATA188 and autologous ATA190 that are in Phase I clinical trials for the treatment of multiple sclerosis; ATA520, a Phase I clinical trial product to treat Wilms tumor 1; and ATA230, which is Phase II clinical trials for refractory cytomegalovirus. In addition, the company is developing ATA368 that is under preclinical development for HIV and cancers. It has license agreements with Memorial Sloan Kettering Cancer Center and Amgen, Inc.; and license, and research and development collaboration agreement with QIMR Berghofer Medical Research Institute. The company was founded in 2012 and is headquartered in South San Francisco, California.

Receive ATRA News and Ratings via Email

Sign-up to receive the latest news and ratings for ATRA and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biological products, except diagnostic

Sub-IndustryN/A

SectorMedical

SymbolNASDAQ:ATRA

CUSIPN/A

Webwww.atarabio.com

Phone650-278-8930

Debt

Debt-to-Equity RatioN/A

Current Ratio19.66

Quick Ratio19.66

Price-To-Earnings

Trailing P/E Ratio-12.76

Forward P/E Ratio-12.57

P/E GrowthN/A

Sales & Book Value

Annual SalesN/A

Price / SalesN/A

Cash FlowN/A

Price / CashN/A

Book Value$9.99 per share

Price / Book5.11

Profitability

EPS (Most Recent Fiscal Year)($4.00)

Net Income$-119,490,000.00

Net MarginsN/A

Return on Equity-51.97%

Return on Assets-46.59%

Miscellaneous

Employees185

Outstanding Shares43,950,000

Atara Biotherapeutics (NASDAQ:ATRA) Frequently Asked Questions

What is Atara Biotherapeutics' stock symbol?

Atara Biotherapeutics trades on the NASDAQ under the ticker symbol "ATRA."

How were Atara Biotherapeutics' earnings last quarter?

Atara Biotherapeutics Inc (NASDAQ:ATRA) issued its quarterly earnings results on Tuesday, May, 8th. The biotechnology company reported ($1.05) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.92) by $0.12. View Atara Biotherapeutics' Earnings History.

What price target have analysts set for ATRA?

9 brokerages have issued 12-month target prices for Atara Biotherapeutics' stock. Their predictions range from $18.00 to $70.00. On average, they anticipate Atara Biotherapeutics' stock price to reach $42.00 in the next year. View Analyst Ratings for Atara Biotherapeutics.

What are Wall Street analysts saying about Atara Biotherapeutics stock?

Here are some recent quotes from research analysts about Atara Biotherapeutics stock:

1. According to Zacks Investment Research, "Atara Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company. It is focused on developing therapeutics for serious unmet medical needs, with an initial focus on muscle wasting conditions and oncology. The company's lead programs are focused on myostatin and activin, members of the TGF-beta family of proteins that have demonstrated the potential to have therapeutic benefit in a number of clinical indications. Its lead product candidate is PINTA 745, which is in a Phase II clinical trial for the treatment of protein-energy wasting in end-stage renal disease patients. Atara Biotherapeutics, Inc. is headquartered in Brisbane, California. " (5/10/2018)
2. Canaccord Genuity analysts commented, "We are updating details of our model and valuation table for ATRA, but our price target remains at $70 and our revenue estimates remain unchanged." (3/13/2018)

Who are some of Atara Biotherapeutics' key competitors?

Some companies that are related to Atara Biotherapeutics include Neurocrine Biosciences (NBIX), Qiagen (QGEN), AveXis (AVXS), Bio-Techne (TECH), CRISPR Therapeutics (CRSP), arGEN-X BV (ARGX), Spark Therapeutics (ONCE), Halozyme Therapeutics (HALO), China Biologic Products (CBPO), Aerie Pharmaceuticals (AERI), Denali Therapeutics (DNLI), Momenta Pharmaceuticals (MNTA), Repligen (RGEN), Editas Medicine (EDIT) and Acceleron Pharma (XLRN).

Who are Atara Biotherapeutics' key executives?

Atara Biotherapeutics' management team includes the folowing people:

Dr. Isaac E. Ciechanover, Pres, CEO & Director (Age 47)
Mr. Joseph Newell, Exec. VP & Chief Technical Operations Officer (Age 48)
Dr. Derrell D. Porter, Sr. VP & Global Commercial Head (Age 47)
Dr. Christopher M. Haqq, Exec. VP of R&D & Chief Scientific Officer (Age 52)
John Craighead, VP of Investor Relations & Corp. Communications

Has Atara Biotherapeutics been receiving favorable news coverage?

Media headlines about ATRA stock have trended somewhat positive this week, according to Accern. The research firm rates the sentiment of media coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Atara Biotherapeutics earned a media sentiment score of 0.23 on Accern's scale. They also gave media coverage about the biotechnology company an impact score of 45.35 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company's share price in the next few days.

Who are Atara Biotherapeutics' major shareholders?

Atara Biotherapeutics' stock is owned by many different of retail and institutional investors. Top institutional investors include FMR LLC (17.70%), Redmile Group LLC (9.64%), BlackRock Inc. (6.47%), Artal Group S.A. (2.84%), Neuberger Berman Group LLC (2.49%) and Federated Investors Inc. PA (1.08%). Company insiders that own Atara Biotherapeutics stock include Carol Giltner Gallagher, Christopher Haqq, Derrell Porter, Gad Soffer, Heather D Turner, Isaac E Ciechanover, John Mcgrath, Matthew K Fust and Mitchall G Clark. View Institutional Ownership Trends for Atara Biotherapeutics.

Which major investors are selling Atara Biotherapeutics stock?

ATRA stock was sold by a variety of institutional investors in the last quarter, including Old West Investment Management LLC and Her Majesty the Queen in Right of the Province of Alberta as represented by Alberta Investment Management Corp. Company insiders that have sold Atara Biotherapeutics company stock in the last year include Carol Giltner Gallagher, Christopher Haqq, Derrell Porter, Gad Soffer, Heather D Turner, Isaac E Ciechanover, John Mcgrath, Matthew K Fust and Mitchall G Clark. View Insider Buying and Selling for Atara Biotherapeutics.

Which major investors are buying Atara Biotherapeutics stock?

ATRA stock was bought by a variety of institutional investors in the last quarter, including Redmile Group LLC, BlackRock Inc., Federated Investors Inc. PA, PointState Capital LP, Artal Group S.A., Northern Trust Corp, UBS Group AG and Pacific Heights Asset Management LLC. View Insider Buying and Selling for Atara Biotherapeutics.

How do I buy shares of Atara Biotherapeutics?

Shares of ATRA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Atara Biotherapeutics' stock price today?

One share of ATRA stock can currently be purchased for approximately $51.05.

How big of a company is Atara Biotherapeutics?

Atara Biotherapeutics has a market capitalization of $2.18 billion. The biotechnology company earns $-119,490,000.00 in net income (profit) each year or ($4.00) on an earnings per share basis. Atara Biotherapeutics employs 185 workers across the globe.

How can I contact Atara Biotherapeutics?

Atara Biotherapeutics' mailing address is 611 GATEWAY BLVD SUITE 900, SOUTH SAN FRANCISCO CA, 94080. The biotechnology company can be reached via phone at 650-278-8930.

MarketBeat Community Rating for Atara Biotherapeutics (ATRA)

Community Ranking:		3.1 out of 5 ( )
Outperform Votes:		236 (Vote Outperform)
Underperform Votes:		148 (Vote Underperform)
Total Votes:		384

MarketBeat's community ratings are surveys of what our community members think about Atara Biotherapeutics and other stocks. Vote "Outperform" if you believe ATRA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ATRA will underperform the S&P 500 over the long term. You may vote once every thirty days.

Atara Biotherapeutics (NASDAQ:ATRA) Price Target and Consensus Rating

(How are Consensus Ratings Calculated?)

9 Wall Street analysts have issued ratings and price targets for Atara Biotherapeutics in the last 12 months. Their average twelve-month price target is $42.00, suggesting that the stock has a possible downside of 17.73%. The high price target for ATRA is $70.00 and the low price target for ATRA is $18.00. There are currently 1 sell rating, 3 hold ratings and 5 buy ratings for the stock, resulting in a consensus rating of "Hold."

	Today	30 Days Ago	90 Days Ago	180 Days Ago
Consensus Rating:	Hold	Hold	Buy	Hold
Consensus Rating Score:	2.44	2.44	2.50	2.40
Ratings Breakdown:	1 Sell Rating(s) 3 Hold Rating(s) 5 Buy Rating(s) 0 Strong Buy Rating(s)	1 Sell Rating(s) 3 Hold Rating(s) 5 Buy Rating(s) 0 Strong Buy Rating(s)	1 Sell Rating(s) 1 Hold Rating(s) 4 Buy Rating(s) 0 Strong Buy Rating(s)	1 Sell Rating(s) 1 Hold Rating(s) 3 Buy Rating(s) 0 Strong Buy Rating(s)
Consensus Price Target:	$42.00	$42.00	$34.50	$26.75
Price Target Upside:	17.73% downside	16.67% upside	28.65% downside	100.37% upside

Atara Biotherapeutics (NASDAQ:ATRA) Consensus Price Target History

Price Target History for Atara Biotherapeutics (NASDAQ:ATRA)

Atara Biotherapeutics (NASDAQ:ATRA) Analyst Ratings History

Show:

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
5/8/2018	Canaccord Genuity	Reiterated Rating	Buy	$70.00	Medium
4/10/2018	JPMorgan Chase & Co.	Initiated Coverage	Overweight ➝ Overweight	$56.00	High
4/6/2018	William Blair	Reiterated Rating	Buy		Medium
3/15/2018	Guggenheim	Initiated Coverage	Neutral ➝ Neutral		Low
3/5/2018	Jefferies Group	Boost Price Target	Buy ➝ Buy	$30.00 ➝ $46.00	High
2/28/2018	JMP Securities	Downgrade	Outperform ➝ Market Perform		High
2/15/2018	Citigroup	Downgrade	Neutral ➝ Sell		High
1/26/2018	Cowen	Initiated Coverage	Outperform		High
10/6/2017	Goldman Sachs Group	Reiterated Rating	Neutral ➝ Neutral	$20.00	N/A

(Data available from 5/25/2016 forward)

Atara Biotherapeutics (NASDAQ:ATRA) Earnings History and Estimates Chart

Earnings by Quarter for Atara Biotherapeutics (NASDAQ:ATRA)

Atara Biotherapeutics (NASDAQ:ATRA) Earnings Estimates

2018 EPS Consensus Estimate: ($3.93)
2019 EPS Consensus Estimate: ($4.69)

Quarter	Number of Estimates	Low Estimate	High Estimate	Average Estimate
Q1 2018	2	($0.96)	($0.85)	($0.91)
Q2 2018	2	($0.98)	($0.97)	($0.98)
Q3 2018	2	($1.02)	($0.98)	($1.00)
Q4 2018	2	($1.06)	($1.03)	($1.05)
Q1 2019	1	($1.15)	($1.15)	($1.15)
Q2 2019	1	($1.24)	($1.24)	($1.24)
Q3 2019	1	($1.17)	($1.17)	($1.17)
Q4 2019	1	($1.13)	($1.13)	($1.13)

Atara Biotherapeutics (NASDAQ ATRA) Earnings History by Quarter

Date	Quarter	Consensus Estimate	Actual EPS	Release Link	Conference Call
5/8/2018	Q1 2018	($0.9230)	($1.0470)	View	N/A
2/27/2018	Q4 2017	($1.15)	($1.15)	View	N/A
11/9/2017	Q3 2017	($0.97)	($1.02)	View	N/A
8/7/2017	Q2 2017	($0.89)	($0.94)	View	N/A
5/4/2017	Q1 2017	($0.77)	($0.88)	View	N/A
3/9/2017	12/31/2016	($0.98)	($0.63)	View	N/A
11/4/2016	Q3 2016	($0.79)	($0.88)	View	N/A
8/8/2016	Q2	($0.61)	($0.66)	View	N/A
5/5/2016	Q1	($0.55)	($0.58)	View	N/A
3/3/2016	Q4 2015	($0.48)	($0.75)	View	N/A
11/5/2015	Q3 2015	($0.53)	($0.43)	View	N/A
8/6/2015	Q215	($0.42)	($0.43)	View	N/A
5/7/2015	Q1 2015	($0.36)	($0.42)	View	N/A
2/26/2015	Q4 2014	($0.35)	($0.67)	View	N/A
11/12/2014	Q314		($4.20)	View	N/A

(Earnings results data provided by Zacks Investment Research)

Atara Biotherapeutics (NASDAQ:ATRA) Dividend History by Quarter

Announced	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date

(Data available from 1/1/2013 forward)

Atara Biotherapeutics (NASDAQ ATRA) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 10.60%

Insider Trading History for Atara Biotherapeutics (NASDAQ:ATRA)

Atara Biotherapeutics (NASDAQ ATRA) Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
5/22/2018	Isaac E Ciechanover	CEO	Sell	8,800	$51.74	$455,312.00	812,613
5/18/2018	Mitchall G Clark	EVP	Sell	25,860	$50.03	$1,293,775.80	107,972
5/16/2018	Carol Giltner Gallagher	Director	Sell	273	$46.06	$12,574.38	111,465
5/16/2018	Mitchall G Clark	EVP	Sell	4,647	$46.06	$214,040.82	357,905
5/15/2018	Derrell Porter	SVP	Sell	16,334	$45.02	$735,356.68	28,834
5/14/2018	Matthew K Fust	Director	Sell	12,286	$43.57	$535,301.02	19,820
5/10/2018	Isaac E Ciechanover	CEO	Sell	8,800	$39.85	$350,680.00	812,613
5/8/2018	Derrell Porter	SVP	Sell	1,544	$40.15	$61,991.60	12,500
4/27/2018	Isaac E Ciechanover	CEO	Sell	8,800	$42.46	$373,648.00
4/11/2018	Isaac E Ciechanover	CEO	Sell	4,400	$40.82	$179,608.00	812,613
3/29/2018	Mitchall G Clark	EVP	Sell	22,400	$40.07	$897,568.00
3/26/2018	Christopher Haqq	EVP	Sell	18,327	$39.79	$729,231.33	334,005
3/26/2018	Isaac E Ciechanover	CEO	Sell	4,400	$40.10	$176,440.00	206,478
3/20/2018	John Mcgrath	CFO	Sell	6,000	$40.41	$242,460.00	91,762
3/16/2018	Isaac E Ciechanover	CEO	Sell	8,800	$42.13	$370,744.00	812,613
3/12/2018	Isaac E Ciechanover	CEO	Sell	1,000	$46.31	$46,310.00	812,613
2/22/2018	Isaac E Ciechanover	CEO	Sell	17,800	$44.65	$794,770.00	812,613
2/20/2018	Isaac E Ciechanover	CEO	Sell	8,700	$45.28	$393,936.00	812,613
2/16/2018	Carol Giltner Gallagher	Director	Sell	1,183	$46.50	$55,009.50	111,286
2/16/2018	Isaac E Ciechanover	CEO	Sell	20,000	$46.92	$938,400.00	812,613
2/16/2018	John Mcgrath	CFO	Sell	13,000	$47.07	$611,910.00	99,056
2/14/2018	Isaac E Ciechanover	CEO	Sell	20,000	$46.80	$936,000.00	808,675
2/9/2018	Heather D Turner	EVP	Sell	12,214	$38.01	$464,254.14	77,112
2/9/2018	Isaac E Ciechanover	CEO	Sell	8,800	$37.44	$329,472.00	808,675
1/26/2018	Isaac E Ciechanover	CEO	Sell	19,300	$35.26	$680,518.00	743,675
1/24/2018	Isaac E Ciechanover	CEO	Sell	48,500	$34.58	$1,677,130.00	348,978
1/22/2018	Isaac E Ciechanover	CEO	Sell	10,000	$33.07	$330,700.00	348,978
1/16/2018	Isaac E Ciechanover	CEO	Sell	600	$30.38	$18,228.00	743,675
1/12/2018	Isaac E Ciechanover	CEO	Sell	28,700	$21.39	$613,893.00	743,675
1/12/2018	John Mcgrath	CFO	Sell	37,000	$24.35	$900,950.00	93,154
1/10/2018	Isaac E Ciechanover	CEO	Sell	8,600	$19.99	$171,914.00	743,675
12/29/2017	Isaac E Ciechanover	CEO	Sell	22,200	$18.29	$406,038.00
12/29/2017	John Mcgrath	CFO	Sell	32,000	$20.00	$640,000.00
12/29/2017	John Mcgrath	CFO	Sell	32,000	$20.00	$640,000.00	96,654
12/28/2017	Isaac E Ciechanover	CEO	Sell	2,200	$15.15	$33,330.00	743,675
12/13/2017	Isaac E Ciechanover	CEO	Sell	4,400	$14.65	$64,460.00	743,675
11/30/2017	Isaac E Ciechanover	CEO	Sell	4,400	$14.25	$62,700.00
11/17/2017	Gad Soffer	EVP	Sell	7,000	$15.00	$105,000.00	166,342
11/16/2017	Carol Giltner Gallagher	Director	Sell	1,184	$14.20	$16,812.80	110,105
11/15/2017	Christopher Haqq	EVP	Sell	1,604	$13.36	$21,429.44	344,134
11/14/2017	Isaac E Ciechanover	CEO	Sell	4,400	$13.47	$59,268.00	737,767
10/27/2017	Isaac E Ciechanover	CEO	Sell	4,400	$13.59	$59,796.00	737,767
10/16/2017	Christopher Haqq	EVP	Sell	6,000	$14.35	$86,100.00
10/12/2017	Isaac E Ciechanover	CEO	Sell	4,400	$15.02	$66,088.00
10/11/2017	Isaac E Ciechanover	CEO	Sell	2,200	$15.25	$33,550.00	737,767
9/20/2017	Isaac E Ciechanover	CEO	Sell	4,400	$15.54	$68,376.00	737,767
9/15/2017	Christopher Haqq	EVP	Sell	6,000	$15.30	$91,800.00	349,305
9/7/2017	Isaac E Ciechanover	CEO	Sell	4,400	$15.02	$66,088.00	737,767
8/23/2017	Isaac E Ciechanover	CEO	Sell	4,400	$13.54	$59,576.00	737,767
8/16/2017	Carol Giltner Gallagher	Director	Sell	1,184	$14.30	$16,931.20	108,922
8/16/2017	John Mcgrath	CFO	Sell	4,200	$14.31	$60,102.00	125,157
8/16/2017	Mitchall G. Clark	EVP	Sell	3,021	$14.33	$43,290.93
8/15/2017	Christopher Haqq	EVP	Sell	7,604	$14.75	$112,159.00	362,909
8/11/2017	Isaac E Ciechanover	CEO	Sell	4,400	$14.67	$64,548.00	731,859
7/25/2017	Isaac E Ciechanover	CEO	Sell	5,500	$16.49	$90,695.00	731,859
7/24/2017	Isaac E Ciechanover	CEO	Sell	2,800	$16.94	$47,432.00	731,859
7/17/2017	Christopher Haqq	EVP	Sell	6,000	$14.92	$89,520.00	362,080
6/15/2017	Christopher Haqq	EVP	Sell	6,000	$12.65	$75,900.00	368,080
6/9/2017	Carol Giltner Gallagher	Director	Sell	1,000	$13.15	$13,150.00	108,374
5/31/2017	Isaac E Ciechanover	CEO	Sell	6,900	$13.35	$92,115.00	731,859
5/30/2017	Isaac E Ciechanover	CEO	Sell	3,450	$13.44	$46,368.00	731,859
5/18/2017	Isaac E Ciechanover	CEO	Sell	4,800	$14.91	$71,568.00	731,859
5/16/2017	Carol Giltner Gallagher	Director	Sell	1,184	$15.25	$18,056.00	103,741
5/16/2017	Gad Soffer	EVP	Sell	12,674	$15.16	$192,137.84	259,527
5/16/2017	John Mcgrath	CFO	Sell	4,000	$15.11	$60,440.00	113,762
4/26/2017	Isaac E Ciechanover	CEO	Sell	7,200	$17.56	$126,432.00	725,951
4/25/2017	Isaac E Ciechanover	CEO	Sell	3,600	$17.33	$62,388.00	725,951
4/17/2017	Christopher Haqq	EVP	Sell	6,000	$17.28	$103,680.00	380,855
4/11/2017	Isaac E Ciechanover	CEO	Sell	7,200	$17.03	$122,616.00	725,951
3/28/2017	Isaac E Ciechanover	CEO	Sell	16,000	$20.06	$320,960.00	725,951
3/23/2017	John Mcgrath	CFO	Sell	14,000	$20.65	$289,100.00	119,327
3/17/2017	Isaac E Ciechanover	CEO	Sell	30,800	$19.38	$596,904.00	725,951
3/10/2017	Gad Soffer	EVP	Sell	2,500	$20.00	$50,000.00	266,527
3/10/2017	John Mcgrath	CFO	Sell	24,000	$20.00	$480,000.00	126,827
2/21/2017	John Mcgrath	CFO	Sell	9,000	$15.14	$136,260.00	150,827
2/16/2017	Carol Giltner Gallagher	Director	Sell	1,183	$16.10	$19,046.30	102,558
2/16/2017	Isaac E Ciechanover	CEO	Sell	4,800	$15.56	$74,688.00	725,951
2/16/2017	Mitchall G. Clark	EVP	Sell	3,059	$15.96	$48,821.64
2/15/2017	Christopher Haqq	EVP	Sell	7,604	$15.49	$117,785.96	400,459
2/10/2017	Gad Soffer	EVP	Sell	6,274	$15.47	$97,058.78	269,938
2/9/2017	Christopher Haqq	EVP	Sell	13,975	$15.46	$216,053.50	399,630
2/3/2017	Isaac E Ciechanover	CEO	Sell	4,800	$13.66	$65,568.00	555,044
1/18/2017	Isaac E Ciechanover	CEO	Sell	6,000	$14.24	$85,440.00	555,044
1/17/2017	Christopher Haqq	EVP	Sell	6,000	$14.27	$85,620.00	364,105
1/6/2017	Isaac E Ciechanover	CEO	Sell	8,400	$16.89	$141,876.00	555,044
12/23/2016	Isaac E Ciechanover	CEO	Sell	4,800	$15.22	$73,056.00	555,044
12/15/2016	Christopher Haqq	Insider	Sell	6,000	$15.40	$92,400.00	370,105
12/7/2016	Isaac E Ciechanover	CEO	Sell	7,200	$17.93	$129,096.00	555,044
11/23/2016	Isaac E Ciechanover	CEO	Sell	12,000	$18.34	$220,080.00	555,044
11/22/2016	Isaac E Ciechanover	CEO	Sell	8,400	$18.21	$152,964.00	555,044
11/16/2016	Carol Giltner Gallagher	Director	Sell	1,184	$19.35	$22,910.40	99,377
11/16/2016	Gad Soffer	COO	Sell	16,718	$20.00	$334,360.00	225,667
11/16/2016	Mitchall G Clark	Insider	Sell	2,995	$19.53	$58,492.35	98,182
11/14/2016	Gad Soffer	COO	Sell	9,582	$20.55	$196,910.10	225,667
11/11/2016	John Mcgrath	CFO	Sell	5,000	$19.84	$99,200.00	91,823
10/27/2016	Isaac E Ciechanover	CEO	Sell	4,800	$13.81	$66,288.00	549,136
10/14/2016	Isaac E Ciechanover	CEO	Sell	4,800	$15.96	$76,608.00	549,136
10/12/2016	John Mcgrath	CFO	Sell	5,000	$17.47	$87,350.00	96,823
9/28/2016	Isaac E Ciechanover	CEO	Sell	12,000	$20.87	$250,440.00	406,578
9/16/2016	Isaac E Ciechanover	CEO	Sell	7,200	$19.36	$139,392.00	229,136
8/23/2016	Isaac E Ciechanover	CEO	Sell	9,600	$22.33	$214,368.00	229,136
8/16/2016	Gad Soffer	COO	Sell	5,356	$22.41	$120,027.96	146,460
8/15/2016	Christopher Haqq	Insider	Sell	1,346	$22.32	$30,042.72	295,294
7/21/2016	Isaac E Ciechanover	CEO	Sell	9,600	$22.11	$212,256.00	223,228
7/8/2016	Isaac E Ciechanover	CEO	Sell	9,600	$22.88	$219,648.00	223,228
6/24/2016	Isaac E Ciechanover	CEO	Sell	9,600	$21.26	$204,096.00	223,228
6/8/2016	Isaac E Ciechanover	CEO	Sell	12,000	$20.53	$246,360.00	223,228
6/7/2016	Isaac E Ciechanover	CEO	Sell	7,200	$20.36	$146,592.00	223,228
5/26/2016	Isaac E Ciechanover	CEO	Sell	7,200	$17.69	$127,368.00	223,228
5/18/2016	Carol Giltner Gallagher	Director	Sell	1,184	$15.96	$18,896.64	95,829
5/17/2016	Gad Soffer	COO	Sell	5,427	$15.91	$86,343.57	138,125
5/16/2016	John Mcgrath	CFO	Sell	5,395	$15.77	$85,079.15	86,519
5/16/2016	Mitchall G Clark	Insider	Sell	4,153	$15.15	$62,917.95	87,912
4/26/2016	Isaac E Ciechanover	CEO	Sell	1,300	$20.12	$26,156.00	217,321
4/12/2016	Isaac E Ciechanover	CEO	Sell	13,210	$20.40	$269,484.00	217,321
4/1/2016	Isaac E Ciechanover	CEO	Sell	1,190	$20.03	$23,835.70	217,321
3/17/2016	Eric Dobmeier	Director	Buy	3,000	$13.86	$41,580.00	5,500
2/17/2016	Carol Giltner Gallagher	Director	Sell	1,183	$16.30	$19,282.90	94,280
2/17/2016	Gad Soffer	COO	Sell	5,711	$16.77	$95,773.47	128,510
1/14/2016	Isaac E Ciechanover	CEO	Sell	2,400	$20.20	$48,480.00	47,440
12/31/2015	Isaac E Ciechanover	CEO	Sell	2,400	$26.00	$62,400.00	47,440
12/16/2015	Eric Dobmeier	Director	Buy	2,500	$22.00	$55,000.00	2,500
12/15/2015	Isaac E Ciechanover	CEO	Sell	2,400	$22.46	$53,904.00	47,440
12/4/2015	Isaac E Ciechanover	CEO	Sell	4,000	$37.45	$149,800.00	47,440
11/30/2015	John Mcgrath	CFO	Sell	6,000	$40.00	$240,000.00	36,356
11/24/2015	Isaac E Ciechanover	CEO	Sell	4,800	$35.03	$168,144.00	47,440
11/17/2015	Carol Giltner Gallagher	Director	Sell	1,184	$31.10	$36,822.40	93,098
11/17/2015	Gad Soffer	COO	Sell	7,586	$31.22	$236,834.92	72,013
10/22/2015	Isaac E Ciechanover	CEO	Sell	3,200	$25.85	$82,720.00	41,532
10/7/2015	Isaac E Ciechanover	CEO	Sell	4,000	$33.08	$132,320.00	41,532
9/24/2015	Isaac E Ciechanover	CEO	Sell	5,200	$42.99	$223,548.00	41,532
9/11/2015	Isaac E. Ciechanover	CEO	Sell	5,200	$46.16	$240,032.00	41,532
8/31/2015	Christopher Haqq	insider	Sell	5,000	$41.99	$209,950.00	240,890
8/28/2015	Isaac E Ciechanover	CEO	Sell	5,200	$39.25	$204,100.00	41,532
8/24/2015	Carol Giltner Gallagher	Director	Sell	17,622	$42.34	$746,115.48	91,916
8/19/2015	Carol Giltner Gallagher	Director	Sell	5,875	$48.18	$283,057.50
8/18/2015	Carol Giltner Gallagher	Director	Sell	5,764	$49.38	$284,626.32
8/18/2015	Gad Soffer	COO	Sell	7,711	$49.49	$381,617.39
8/18/2015	John Mcgrath	CFO	Sell	6,000	$49.38	$296,280.00
8/17/2015	Gad Soffer	COO	Sell	8,778	$50.00	$438,900.00
8/17/2015	Mitchall G Clark	Insider	Sell	7,829	$46.19	$361,621.51
7/17/2015	Isaac E Ciechanover	CEO	Sell	5,200	$60.71	$315,692.00
7/15/2015	Christopher Haqq	Insider	Sell	2,500	$62.94	$157,350.00
7/1/2015	Christopher Haqq	Insider	Sell	2,500	$51.68	$129,200.00
7/1/2015	Isaac E Ciechanover	CEO	Sell	5,200	$50.42	$262,184.00
6/18/2015	Isaac E Ciechanover	CEO	Sell	5,200	$54.72	$284,544.00
6/15/2015	Christopher Haqq	Insider	Sell	7,500	$46.42	$348,150.00
6/15/2015	John Mcgrath	CFO	Sell	10,000	$50.00	$500,000.00
6/5/2015	Isaac E Ciechanover	CEO	Sell	6,400	$42.91	$274,624.00
6/1/2015	Christopher Haqq	Insider	Sell	2,500	$41.47	$103,675.00
5/29/2015	John Mcgrath	CFO	Sell	10,000	$40.00	$400,000.00
5/22/2015	Isaac E Ciechanover	CEO	Sell	4,000	$37.56	$150,240.00
4/23/2015	Isaac E Ciechanover	CEO	Sell	5,200	$61.36	$319,072.00
3/10/2015	Joel S Marcus	Director	Buy	4,000	$29.57	$118,280.00
2/18/2015	Carol Giltner Gallagher	Director	Buy	11,000	$18.00	$198,000.00
10/21/2014	Domain Partners Viii, L.P.	Major Shareholder	Buy	248,159	$11.00	$2,729,749.00

(Data available from 1/1/2013 forward)

Atara Biotherapeutics (NASDAQ ATRA) News Headlines

Source:

Date	Headline
	Atara Biotherapeutics (ATRA) CEO Sells $455,312.00 in Stock www.americanbankingnews.com - May 22 at 7:28 PM
	Insider Selling: Atara Biotherapeutics (ATRA) EVP Sells 25,860 Shares of Stock www.americanbankingnews.com - May 21 at 7:17 PM
	Atara Biotherapeutics: What Q1 2018 Earnings Foretell? seekingalpha.com - May 18 at 9:21 AM
	Atara Biotherapeutics to Present Long-Term Tab-cel™ Phase 2 Clinical Outcomes for Patients with Epstein-Barr Virus ... globenewswire.com - May 17 at 5:38 PM
	Atara Biotherapeutics to Present Long-Term Tab-cel™ Phase 2 Clinical Outcomes for Patients with Epstein-Barr Virus Associated Post-Transplant Lymphomas at 23rd Congress of European Hematology Association finance.yahoo.com - May 17 at 5:38 PM
	Atara Biotherapeutics (ATRA) Given Consensus Rating of "Buy" by Brokerages www.americanbankingnews.com - May 17 at 1:51 PM
	Atara Biotherapeutics: A Gift That Keeps On Giving seekingalpha.com - May 17 at 8:56 AM
	Insider Selling: Atara Biotherapeutics (ATRA) EVP Sells 4,647 Shares of Stock www.americanbankingnews.com - May 16 at 10:29 PM
	Insider Selling: Atara Biotherapeutics (ATRA) Director Sells 273 Shares of Stock www.americanbankingnews.com - May 16 at 10:28 PM
	Atara Biotherapeutics (ATRA) Director Matthew K. Fust Sells 12,286 Shares www.americanbankingnews.com - May 16 at 10:16 PM
	Atara Biotherapeutics (ATRA) SVP Derrell Porter Sells 16,334 Shares www.americanbankingnews.com - May 16 at 10:15 PM
	Q2 2018 Earnings Estimate for Atara Biotherapeutics Issued By Jefferies Group (ATRA) www.americanbankingnews.com - May 14 at 2:48 AM
	Atara Biotherapeutics: What The Q1 2018 Earnings Foretell? seekingalpha.com - May 13 at 9:02 AM
	Rounds Report: Omeros Rallied While Stellar FDA Due Diligence To Help Atara Biotherapeutics seekingalpha.com - May 13 at 9:02 AM
	Rounds Report: Omeros Rallied While The Stellar FDA Due Diligence To Help Atara seekingalpha.com - May 12 at 9:10 AM
	Atara Biotherapeutics (ATRA) CEO Sells $350,680.00 in Stock www.americanbankingnews.com - May 10 at 10:15 PM
	Zacks: Analysts Expect Atara Biotherapeutics (ATRA) to Post -$0.89 EPS www.americanbankingnews.com - May 10 at 9:23 PM
	Atara Biotherapeutics (ATRA) Issues Earnings Results www.americanbankingnews.com - May 10 at 6:12 PM
	Zacks Investment Research Lowers Atara Biotherapeutics (ATRA) to Sell www.americanbankingnews.com - May 10 at 5:36 PM
	Q2 2018 EPS Estimates for Atara Biotherapeutics (ATRA) Reduced by Analyst www.americanbankingnews.com - May 10 at 7:26 AM
	Form 4 Atara Biotherapeutics, For: May 08 Filed by: Porter Derrell www.streetinsider.com - May 9 at 8:50 AM
	BRIEF-Atara Biotherapeutics Expands T-Cell Immunotherapy Collaboration www.reuters.com - May 9 at 8:50 AM
	BRIEF-Atara Biotherapeutics Reports Q1 Loss Per Share $1.05 www.reuters.com - May 9 at 8:50 AM
	Biotech Industry Veteran Dietmar Berger, MD, Ph.D., Joins Atara Biotherapeutics as Global Head of Research and ... globenewswire.com - May 9 at 8:50 AM
	Atara Biotherapeutics (ATRA) SVP Sells $61,991.60 in Stock www.americanbankingnews.com - May 8 at 10:28 PM
	Atara Biotherapeutics (ATRA) Earns "Buy" Rating from Canaccord Genuity www.americanbankingnews.com - May 8 at 9:15 PM
	Atara Biotherapeutics: 1Q Earnings Snapshot finance.yahoo.com - May 8 at 8:46 AM
	Biotech Industry Veteran Dietmar Berger, M.D., Ph.D., Joins Atara Biotherapeutics as Global Head of Research and Development finance.yahoo.com - May 7 at 8:44 AM
	Atara Biotherapeutics (ATRA) Upgraded by ValuEngine to "Strong-Buy" www.americanbankingnews.com - May 4 at 12:21 AM
	Atara Biotherapeutics (ATRA) Rating Increased to Buy at Zacks Investment Research www.americanbankingnews.com - May 1 at 7:10 PM
	Isaac E. Ciechanover Sells 8,800 Shares of Atara Biotherapeutics (ATRA) Stock www.americanbankingnews.com - April 30 at 7:44 PM
	Atara Biotherapeutics (ATRA) Upgraded to "Buy" by BidaskClub www.americanbankingnews.com - April 26 at 1:31 PM
	-$0.93 Earnings Per Share Expected for Atara Biotherapeutics (ATRA) This Quarter www.americanbankingnews.com - April 23 at 11:18 AM
	Atara Biotherapeutics (ATRA) Receives Average Recommendation of "Hold" from Brokerages www.americanbankingnews.com - April 22 at 1:36 PM
	3 Growth Stocks for Successful Investors finance.yahoo.com - April 21 at 4:58 PM
	Reader Inquiry: What's The Outlook For Atara Biotherapeutics After The Recent Secondary? seekingalpha.com - April 20 at 8:53 AM
	Atara Biotherapeutics (ATRA) Downgraded to Strong Sell at ValuEngine www.americanbankingnews.com - April 14 at 2:30 PM
	Insider Selling: Atara Biotherapeutics (ATRA) CEO Sells 4,400 Shares of Stock www.americanbankingnews.com - April 12 at 7:37 PM
	Atara Biotherapeutics (ATRA) Earns Overweight Rating from Analysts at JPMorgan Chase www.americanbankingnews.com - April 10 at 8:39 AM
	Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) finance.yahoo.com - April 9 at 4:59 PM
	-$0.91 EPS Expected for Atara Biotherapeutics (ATRA) This Quarter www.americanbankingnews.com - April 6 at 1:14 PM
	Atara Biotherapeutics (ATRA) Receives "Buy" Rating from William Blair www.americanbankingnews.com - April 6 at 11:31 AM
	Atara Biotherapeutics (ATRA) Downgraded to "Hold" at BidaskClub www.americanbankingnews.com - April 5 at 2:08 PM
	Atara Biotherapeutics Forecasted to Post Q1 2019 Earnings of ($1.06) Per Share (ATRA) www.americanbankingnews.com - April 4 at 7:58 AM
	Atara Biotherapeutics (ATRA) EVP Mitchall G. Clark Sells 22,400 Shares www.americanbankingnews.com - April 3 at 10:10 PM
	Atara Biotherapeutics (ATRA) Upgraded to "Buy" by ValuEngine www.americanbankingnews.com - April 3 at 6:58 PM
	Atara Biotherapeutics (ATRA) Upgraded at Citigroup www.americanbankingnews.com - March 31 at 12:12 AM
	Form 4 Atara Biotherapeutics, For: Mar 26 Filed by: Ciechanover Isaac E. www.streetinsider.com - March 29 at 8:58 AM
	Atara Biotherapeutics (ATRA) Upgraded by BidaskClub to "Buy" www.americanbankingnews.com - March 28 at 9:48 PM
	Atara Biotherapeutics Inc (ATRA) Receives Average Rating of "Hold" from Analysts www.americanbankingnews.com - March 28 at 1:10 PM

Atara Biotherapeutics (NASDAQ:ATRA) SEC Filings

Form Type:

Ownership Filings:

This page is loading this company's SEC Filings. Please wait...

Atara Biotherapeutics (NASDAQ:ATRA) Income Statement, Balance Sheet and Cash Flow Statement

Atara Biotherapeutics (NASDAQ ATRA) Stock Chart for Friday, May, 25, 2018

Loading chart…

This page was last updated on 5/25/2018 by MarketBeat.com Staff